Role of faecal calprotectin as non-invasive marker of intestinal inflammation

Digestive and Liver Disease

Volumn 35, Issue 9, 2003, Pages 642-647

  Costa, F ^a   Mumolo, M G ^a   Bellini, M ^a   Romano, M R ^a   Ceccarelli, L ^a   Arpe, P ^a   Sterpi, C ^a   Marchi, S ^a   Maltinti, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Calprotectin; Inflammatory bowel diseases; Irritable bowel syndrome

Indexed keywords

CALPROTECTIN; BIOLOGICAL MARKER; CALGRANULIN;

ADULT; AGED; ARTICLE; CHI SQUARE TEST; CHRONIC DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENTERITIS; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FECES LEVEL; FEMALE; FISHER EXACT TEST; FOLLOW UP; HUMAN; INTESTINE TUMOR; IRRITABLE COLON; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; ULCERATIVE COLITIS; CASE CONTROL STUDY; CHEMISTRY; FECES; PATHOLOGY;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL NEOPLASMS; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 1542394043     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00381-5     Document Type: Article

References (35)

1. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol MK, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402-8.
2. Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:675-81.
3. Andus T, Gross V, Caesar I, Krumm D, Hosp J, Gerok W, et al. PMN-elastase in the assessment of patients with inflammatory bowel disease. Dig Dis Sci 1993;38:1638-44.
4. Bohe M, Genell S, Ohlsson K. Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease. Scand J Gastroenterol 1986;21:598-604.
5. Brouwer J. Semiquantitative determination of faecal leukocyte esterase by a dip-and-read assay. Clin Chem 1993;39:2531-2.
6. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927-34.
7. Meyers S, Wolke A, Field SP, Feuer EJ, Johnson JW, Janowitz HD. Fecal α1-antitrypsin measurements: an indicator of Crohn's disease activity. Gastroenterology 1985;89:13-8.
8. Catassi C, Cardinali E, D'Angelo G, Coppa GV, Giorgi PL. Reliability of random fecal α1-antitrypsin determination on non dried stools. J Pediat 1986;109:500-2.
9. 111Indium granulocytes in the assessment of disease activity in chronic inflammatory bowel diseases. Gut 1987;28:386-9.
10. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the LI antigen. Eur J Biochem 1983;134:1-6.
11. Fagerhol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (the LI leukocyte protein). In: Smith V, Dedman JR, editors, Stimulus response coupling: the role of intracellular calcium-binding proteins, Boca Raton, FL: CRC Press; 1990, pp. 187-210.
12. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte LI protein, calprotectin. Lancet 1990;336:763-5.
13. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113-23.
14. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in faeces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
15. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-6.
16. Tibble JA, Teahon K, Thjodleifsson B, Roseth A, Sightorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
17. Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
18. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonscopy. Am J Gastroenterol 2000;95:2831-7.
19. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of Indium-111-labelled granuylocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4.
20. Best WR, Becktel JM, Singleton JW, Kern Jr. F. Development of a Crohn's disease index; National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989;298:82-6.
22. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl. II):II43-47.
23. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993;30:521-39.
24. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
25. Cronin CC, Shanahan F. Immunological tests to monitor inflammatory bowel disease: have they delivered yet? Am J Gastroenterol 1998;93:295-7.
26. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. New Engl J Med 1999;340:448-54.
27. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP. New insights into the biology of the acute phase response. J Clin Immunol 1999;19:203-14.
28. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
29. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683-7.
30. Grohmann GS, Glass RI, Pereira HG, Monroe SS, Hightower AW, Weber R, et al. Enteric viruses and diarrhea in HIV-infected patients. New Engl J Med 1993;329:14-20.
31. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
32. Arnott IDR, Williams N, Drummond HE, Ghosh S. Whole gut lavage fluid interleukin-1β and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remission. Dig Liver Dis 2002;34:424-9.
33. Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol 1994;89(Suppl. 8):53-65.
34. Kristinsson J, Armbruster C, Ugstad M, Kriwanek S, Nygaard K, Ton H, et al. Fecal excretion of calprotectin in colorectal cancer. Relationship to tumor characteristics. Scand J Gastroenterol 2001;36:202-7.
35. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000;46:795-800.